Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Does Retatrutide Cause Hair Loss? What the Evidence Shows
articleRetatrutide has a small published trial record and no marketed population, so its hair-loss evidence is thin by construction. This guide separates what was reported from what is inference.
Does Semaglutide Cause Hair Loss? (Ozempic & Wegovy Explained)
articleSemaglutide-associated hair shedding is real, and unlike tirzepatide, alopecia is a labeled adverse event in the Wegovy prescribing information. This guide covers mechanism, dose-stratified risk, and the 6-9 month recovery timeline.
Does Tirzepatide Cause Hair Loss? (Mounjaro & Zepbound Explained)
articleTirzepatide-associated hair shedding is real but almost always temporary telogen effluvium triggered by rapid weight loss. This guide covers mechanism, risk factors, prevention, and the 6-12 month recovery timeline.